Lundbeck raises full-year guidance for revenue and adjusted EBITDA, driven by strong Vyepti® growth

Lundbeck has increased its full-year guidance for 2026, with revenue now expected to grow by 11% to 12% CER (previously 7% to 9%) and adjusted EBITDA growth anticipated to be 15% to 19% CER (previously 8% to 14%). This upward revision is attributed to strong performance, particularly from Vyepti®, and solid contributions from Rexulti® across key markets.